Nerve blocks for pain control after open heart surgery through the breastbone
Tests ropivacaine nerve blocks for pain after heart surgery in adults.
Plain-language title generated from the registry record
Registry title: Superficial Parasternal Block Combined With Rectus Sheath Block for Open Cardiac Surgery
Key facts
- Where
- Sion, SwitzerlandSee the site
- Phase
- Phase 4
Where in Switzerland
- CHVRSion, SwitzerlandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hôpital du Valais
- Trial code
- NCT07890857
- Record updated
- 22 October 2026
- Original description
The investigators will examine whether the combination of a superficial parasternal block and rectus sheath block with multimodal analgesia can enhance postoperative pain control and reduce opioid administration when compared to multimodal analgesia alone, in participants undergoing cardiac surgery and receiving standardized multimodal analgesia.Read full original descriptionShow less
Efficacy of Superficial Parasternal Block Combined With Rectus Sheath Block in Patients Undergoing Cardiac Surgery With Sternotomy A Randomized Controlled, Double Blind Trial (Cardiac Block Trial)
The investigators will examine whether the combination of a superficial parasternal block and rectus sheath block with multimodal analgesia can enhance postoperative pain control and reduce opioid administration when compared to multimodal analgesia alone, in participants undergoing cardiac surgery and receiving standardized multimodal analgesia.
Inclusion: Body weight ≥ 50 kg; Primary cardiac surgery via a median sternotomy approach; Planned for fast-track procedure (i.e. postoperative extubation time of maximum six hours).
Exclusion: • Participation in another study within the 30 days preceding and during the present study; Emergency cardiac surgery; Previous cardiac surgery; Hypersensitivity or allergy to ropivacaine and other amide-class LA; History of chronic pain; History of substance abuse; Renal dysfunction (i.e. creatinine clearance ≤ 30 ml/min); Severe cardiac dysfunction (i.e. LVEF ≤ 35%); Severe obesity (BMI > 40 kg/m2).